Similarly, the outcome of AML improved after anthracycline-based induction therapy was introduced (1980s) [18], allogeneic hematopoietic stem cell transplantation was incorporated (1980s–1990s) [19], and the prognostic significance of certain genetic markers, such as FLT3–ITD and NPM1, was discovered (2000–2005) [20, 21]. This evidence concerns the gene NPM1 and acute myeloid leukemia.